Nicole C Dubois, PhD
- ASSISTANT PROFESSOR | Cell, Developmental & Regenerative Biology
Research Topics:
Cardiovascular, Cellular Differentiation, Developmental Biology, Molecular Biology, Regeneration, Stem CellsIn the Dubois lab we are interested in understanding human heart development and disease. We are using the human pluripotent stem cell (hPSC) model to investigate the cellular and molecular mechanisms of cell fate specification and disease in the early human heart.
For more detailed information please visit us on our lab website http://research.mssm.edu/duboislab/
Multi-Disciplinary Training Areas
Development, Regeneration, and Stem Cells [DRS], Pharmacology and Therapeutics Discovery [PTD]Education
BA, Swiss Federal Institute of Technology Zurich (ETHZ)
PhD, Swiss Institute for Experimental Cancer Research (ISREC)
postdoc, McEwen Centre for Regenerative Medicine Toronto
Yoon C, Song H, Yin T, Bausch-Fluck D, Frei AP, Kattman S, Dubois N, Witty AD, Hewel JA, Guo H, Emili A, Wollscheid B, Keller G, Zandstra PW. FZD4 Marks Lateral Plate Mesoderm and Signals with NORRIN to Increase Cardiomyocyte Induction from Pluripotent Stem Cell-Derived Cardiac Progenitors. Stem cell reports 2018 Jan; 10(1).
Poleshko A, Shah PP, Gupta M, Babu A, Morley MP, Manderfield LJ, Ifkovits JL, Calderon D, Aghajanian H, Sierra-Pagán JE, Sun Z, Wang Q, Li L, Dubois NC, Morrisey EE, Lazar MA, Smith CL, Epstein JA, Jain R. Genome-Nuclear Lamina Interactions Regulate Cardiac Stem Cell Lineage Restriction. Cell 2017 Oct; 171(3).
Bardot E, Tzavaras N, Benson DL, Dubois NC. Quantitative Whole-mount Immunofluorescence Analysis of Cardiac Progenitor Populations in Mouse Embryos. Journal of visualized experiments : JoVE 2017 Oct;(128).
Magadum A, Ding Y, He L, Kim T, Vasudevarao MD, Long Q, Yang K, Wickramasinghe N, Renikunta HV, Dubois N, Weidinger G, Yang Q, Engel FB. Live cell screening platform identifies PPARδ as a regulator of cardiomyocyte proliferation and cardiac repair. Cell research 2017 Aug; 27(8).
Sultana N, Magadum A, Hadas Y, Kondrat J, Singh N, Youssef E, Calderon D, Chepurko E, Dubois N, Hajjar RJ, Zangi L. Optimizing Cardiac Delivery of Modified mRNA. Molecular therapy : the journal of the American Society of Gene Therapy 2017 Jun; 25(6).
Bardot E, Calderon D, Santoriello F, Han S, Cheung K, Jadhav B, Burtscher I, Artap S, Jain R, Epstein J, Lickert H, Gouon-Evans V, Sharp AJ, Dubois NC. Foxa2 identifies a cardiac progenitor population with ventricular differentiation potential. Nature communications 2017 Feb; 8.
Wyatt CM, Dubois N. In vitro generation of renal tubular epithelial cells from fibroblasts: implications for precision and regenerative medicine in nephrology. Kidney international 2017 Feb; 91(2).
Cashman TJ, Josowitz R, Gelb BD, Li RA, Dubois NC, Costa KD. Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy. Journal of visualized experiments : JoVE 2016 Mar;(109).
Zeltner N, Fattahi F, Dubois NC, Saurat N, Lafaille F, Shang L, Zimmer B, Tchieu J, Soliman MA, Lee G, Casanova JL, Studer L. Capturing the biology of disease severity in a PSC-based model of familial dysautonomia. Nature medicine 2016 Dec; 22(12).
Calderon D, Bardot E, Dubois N. Probing early heart development to instruct stem cell differentiation strategies. Developmental dynamics : an official publication of the American Association of Anatomists 2016 Dec; 245(12).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Dubois did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.